Vasomedical reports Q3 results
Vasomedical reported Q3 revenue of $10.8M, down 12.9% year-over-year. Net income from continuing operations fell to $568K from $1.6M in the same period last year. Adjusted EBITDA also decreased to $691K from $1.3M. The company had $53.3M in cash and equivalents.
How this was made
The 30-second read
Why it matters
Traders will likely focus on the direction of revenue and adjusted EBITDA versus expectations, and whether cash levels provide enough runway for continued operations or investment.
Market read
A quarterly earnings release with multiple year-over-year deteriorations can drive near-term repricing, especially for smaller-cap healthcare names.
What to watch
The excerpt lacks guidance, segment detail, and any restructuring or non-recurring items, which could materially change how traders interpret the year-over-year declines.
Background
The piece is a Seeking Alpha writeup of Vasomedical’s Q3 results, citing key income statement and cash figures from the company’s press release.
Ticker impact
Vasomedical (VASO) reported Q3 revenue of $10.8M, down 12.9% Y/Y, with continuing-ops net income of $568k versus $1.6M a year ago.
Likely downside bias as investors weigh weaker top-line and profitability versus expectations.
The article provides multiple year-over-year deteriorations (revenue, net income, adjusted EBITDA) but no forward guidance or one-off explanations, limiting conviction on magnitude of the move.
Market effects
Limited read-through; this is a single-company earnings print with no sector-wide catalyst described.
No specific regional macro or cross-border linkage mentioned.
No global supply, regulation, or cross-market driver cited.
Counterpoint
If the company’s cash position ($53.3M) is improving or burn is controlled, the market may treat the earnings weakness as temporary and focus on liquidity runway.
Key entities
- companyVasomedical
US-listed medical device company reporting Q3 results with declining revenue and profitability year over year.



